Furthermore, significantly increased percentages (Fig. 4C, D, left panels) and absolute numbers of post-therapeutic CD49f+ CD133+ CTCs (Fig. 4C, D, right panels) were found in patients who developed vulvar or cervical cancer relapse. This evidence concerns the gene PROM1 and cervical carcinoma.